ReviewPharmaceutics2022
Nano-Formulation Based Intravesical Drug Delivery Systems: An Overview of Versatile Approaches to Improve Urinary Bladder Diseases.
Review in Pharmaceutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Nanoparticle-based therapeutic platforms for inflammatory disorders of the urinary system: Engineering local delivery, biointerface regulation, and smart responsive therapy.Materials today. Bio · 2026Review
- Triamcinolone acetonide nanoparticles ameliorate interstitial cystitis and anxiety/depression by targeting the bladder-metabolic-brain axis.Materials today. Bio · 2026Article
- Natural Products Targeting Acetylation in Bladder Cancer: Mechanistic Basis, Therapeutic Potential, and Future Perspectives.Current issues in molecular biology · 2026Review
- Nature-Inspired Solutions: Biomimetic Materials and Adaptive Devices for Precision Urinary Oncology.Cancers · 2026Review
- Nanotherapies based on bacterial metabolism: Mechanisms, design and application.Materials today. Bio · 2025Review
- Modulation of Aging Diseases via RAGE Targets: A Dietary Intervention Review.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Kidney and Bladder Transplantation: Advances, Barriers, and Emerging Solutions.Medicina (Kaunas, Lithuania) · 2025Review
- A Comprehensive Review of Current Approaches in Bladder Cancer Treatment.ACS pharmacology & translational science · 2025Review
- Nanostructured Formulations for a Local Treatment of Cancer: A Mini Review About Challenges and Possibilities.Pharmaceutics · 2025Review
- Novel Hydrogel-Mediated Lentiviral Gene Delivery via Intravesical Administration for Bladder Cancer Treatment.Pharmaceutics · 2025Article
- Harnessing natural terpenes via PEGylated mucoadhesive vesicles for improved urinary bladder delivery: fromFrontiers in pharmacology · 2025Article
- Development of Novel Intravesical Formulation for Bladder Retention Targeting Bladder Disorders.Current drug targets · 2025Review
- Targeting tumour surface collage with hydrogel probe: a new strategy to enhance intraoperative imaging sensitivity and stability of bladder cancer.European journal of nuclear medicine and molecular imaging · 2024Article
- Relationship between urinary tract infections and serum vitamin D level in adults and children- a literature review.Molecular biology reports · 2024Review
- Promising Experimental Treatment in Animal Models and Human Studies of Interstitial Cystitis/Bladder Pain Syndrome.International journal of molecular sciences · 2024Review
- Clinical insights into nanomedicine and biosafety: advanced therapeutic approaches for common urological cancers.Frontiers in oncology · 2024Review
- Local Drug Delivery in Bladder Cancer: Advances of Nano/Micro/Macro-Scale Drug Delivery Systems.Pharmaceutics · 2023Review
- Effective Treatments of UTI-Is Intravesical Therapy the Future?Pathogens (Basel, Switzerland) · 2023Review
- Insights into the Safety and Versatility of 4D Printed Intravesical Drug Delivery Systems.Pharmaceutics · 2023Article
- Modulating Inflammation-Mediated Diseases via Natural Phenolic Compounds Loaded in Nanocarrier Systems.Pharmaceutics · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intravesical drug delivery is a direct drug delivery approach for the treatment of various bladder diseases. The human urinary bladder has distinctive anatomy, making it an effective barrier against any toxic agent seeking entry into the bloodstream. This screening function of the bladder derives from the structure of the urothelium, which acts as a semi-permeable barrier. However, various diseases related to the urinary bladder, such as hyperactive bladder syndrome, interstitial cystitis, cancer, urinary obstructions, or urinary tract infections, can alter the bladder's natural function. Consequently, the intravesical route of drug delivery can effectively treat such diseases as it offers site-specific drug action with minimum side effects. Intravesical drug delivery is the direct instillation of medicinal drugs into the urinary bladder via a urethral catheter. However, there are some limitations to this method of drug delivery, including the risk of washout of the therapeutic agents with frequent urination. Moreover, due to the limited permeability of the urinary bladder walls, the therapeutic agents are diluted before the process of permeation, and consequently, their efficiency is compromised. Therefore, various types of nanomaterial-based delivery systems are being employed in intravesical drug delivery to enhance the drug penetration and retention at the targeted site. This review article covers the various nanomaterials used for intravesical drug delivery and future aspects of these nanomaterials for intravesical drug delivery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.